KR101801454B1 - 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 - Google Patents

환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 Download PDF

Info

Publication number
KR101801454B1
KR101801454B1 KR1020157020697A KR20157020697A KR101801454B1 KR 101801454 B1 KR101801454 B1 KR 101801454B1 KR 1020157020697 A KR1020157020697 A KR 1020157020697A KR 20157020697 A KR20157020697 A KR 20157020697A KR 101801454 B1 KR101801454 B1 KR 101801454B1
Authority
KR
South Korea
Prior art keywords
rap
peptide
disease
cyclic
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157020697A
Other languages
English (en)
Korean (ko)
Other versions
KR20150104584A (ko
Inventor
크리스토퍼 엠 스타
토드 씨 잰켈
Original Assignee
랩터 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 랩터 파마슈티컬스 인코포레이티드 filed Critical 랩터 파마슈티컬스 인코포레이티드
Publication of KR20150104584A publication Critical patent/KR20150104584A/ko
Application granted granted Critical
Publication of KR101801454B1 publication Critical patent/KR101801454B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157020697A 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드 Expired - Fee Related KR101801454B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91923807P 2007-03-21 2007-03-21
US60/919,238 2007-03-21
PCT/US2008/057863 WO2008116171A1 (en) 2007-03-21 2008-03-21 Cyclic receptor-associated protein (rap) peptides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097022037A Division KR20100015786A (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Publications (2)

Publication Number Publication Date
KR20150104584A KR20150104584A (ko) 2015-09-15
KR101801454B1 true KR101801454B1 (ko) 2017-11-24

Family

ID=39591450

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097022037A Ceased KR20100015786A (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
KR1020157020697A Expired - Fee Related KR101801454B1 (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020097022037A Ceased KR20100015786A (ko) 2007-03-21 2008-03-21 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드

Country Status (10)

Country Link
US (1) US8440629B2 (enExample)
EP (1) EP2132224B1 (enExample)
JP (1) JP2010524849A (enExample)
KR (2) KR20100015786A (enExample)
CN (1) CN101861334A (enExample)
AT (1) ATE539089T1 (enExample)
BR (1) BRPI0809234A2 (enExample)
CA (1) CA2681522A1 (enExample)
MX (1) MX2009010148A (enExample)
WO (1) WO2008116171A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
MX355683B (es) 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
MX2011004019A (es) 2008-10-15 2011-06-24 Angiochem Inc Conjugados de etoposido y doxorubicina para entrega de farmacos.
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
CN102300987A (zh) 2008-12-17 2011-12-28 安吉奥开米公司 膜型-1基质金属蛋白抑制剂及其用途
US9636384B2 (en) * 2009-04-06 2017-05-02 Mayo Foundation For Medical Education And Research Methods for making polymeric nanoparticle-polypeptide complex
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
TWI558397B (zh) * 2010-01-28 2016-11-21 雷普特製藥有限公司 以受體關連蛋白（ｒａｐ）胜肽－岩藻醣苷水解酶抑制劑共軛物治療肝腫瘤之方法
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
US20180021404A1 (en) * 2015-02-20 2018-01-25 The Regents Of The University Of California Methods and compositions for treating glaucoma
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
CA3083969A1 (en) * 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
EP3902917A4 (en) * 2018-12-27 2022-11-30 bioAffinity Technologies, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
CN116286380B (zh) * 2021-12-21 2026-01-09 暨南大学 环五肽类化合物及其在α-糖苷酶抑制剂类降糖药物或预防保健品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
IT1122765B (it) * 1978-11-06 1986-04-23 Srm Hydromekanik Ab Frizione a dischi multipli
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) * 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6238908B1 (en) * 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US6069167A (en) * 1996-01-16 2000-05-30 University Technology Corporation Use of antioxidant agents to treat cholestatic liver disease
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) * 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) * 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6261595B1 (en) * 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6596762B2 (en) * 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
EP1638605B1 (en) * 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JBC Vol.278(20):17986-17992 (2003)
Journal of Molecular Biology Vol.308(5):1045-1062 (2001)
Molecular Cell Vol.22(2):277-282 (2006)

Also Published As

Publication number Publication date
HK1139162A1 (en) 2010-09-10
ATE539089T1 (de) 2012-01-15
MX2009010148A (es) 2009-12-01
CN101861334A (zh) 2010-10-13
US8440629B2 (en) 2013-05-14
CA2681522A1 (en) 2008-09-25
EP2132224B1 (en) 2011-12-28
US20100210517A1 (en) 2010-08-19
KR20100015786A (ko) 2010-02-12
KR20150104584A (ko) 2015-09-15
WO2008116171A1 (en) 2008-09-25
JP2010524849A (ja) 2010-07-22
BRPI0809234A2 (pt) 2014-09-02
EP2132224A1 (en) 2009-12-16

Similar Documents

Publication Publication Date Title
KR101801454B1 (ko) 환형의 수용체-연관된 단백질(ｒａｐ) 펩티드
JP5840655B2 (ja) Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
EP2370471B1 (en) Neurotensin conjugate and uses thereof
US8877714B2 (en) Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
JP4202250B2 (ja) 血液脳関門輸送を調節するための組成物および方法
CN101878223A (zh) 使用notch途径抑制剂治疗癌症的方法
US9890197B2 (en) RHAMM binding peptides
JP5769420B2 (ja) Ｎｃａｍ由来の新規ペプチド（ｆｇｌｓ）
HK1139162B (en) Cyclic receptor-associated protein (rap) peptides
US20080280833A1 (en) Therapeutic Peptides Derived from Urokinase Plasminogen Activator Receptor
HK1162541B (en) Neurotensin conjugate and uses thereof
HK1162541A (en) Neurotensin conjugate and uses thereof
CN107531802A (zh) 来自肝细胞生长因子/散射因子（hgf/sf）的kringle结构域的多聚体化合物

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

Not in force date: 20201121

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20201121

St.27 status event code: N-4-6-H10-H13-oth-PC1903